Literature DB >> 2060728

Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet beta-cells.

D G Pipeleers1, M Pipeleers-Marichal, B Vanbrabandt, S Duys.   

Abstract

This study examines whether the survival of allografted rat islet beta-cells is influenced by the presence of other pancreatic donor cells. Grafts (RT1u/l) of different cellular composition were intraportally transplanted in streptozocin-induced diabetic rats (RT1n/n). All grafts corrected the diabetic state within 3 days. Implants of freshly isolated islets contained various endocrine and nonendocrine cell types; they became diffusely infiltrated within 1 wk and were completely destroyed within 2 wk. A 4-day culture period did not lead to major changes in the cellular composition of the islets or in their survival as allograft. Islet cell aggregates prepared after islet dissociation and cell purification were less acutely infiltrated and less rapidly rejected. Aggregates composed of sorted MHC class II-negative cells maintained basal normoglycemia in 3 of 5 recipients for 5 wk but only in 1 of 5 for 20 wk. Aggregates of purified islet beta-cells remained relatively free of diffuse infiltrations during the 1st wk and preserved the normalized state in 7 of 13 recipients for 5 wk; after 20 wk, 6 of 13 were still aglucosuric, but 40% of the implants were diffusely infiltrated and depleted of insulin. Reaggregation of purified islet beta-cells with purified islet endocrine non-beta-cells promoted their long-term survival as allograft: 11 of 13 recipients of mixed islet endocrine cells maintained normal basal glycemia over 20 wk; their implants contained relatively constant insulin reserves and remained virtually devoid of diffuse infiltrations. These results demonstrate that techniques aiming at the elimination of surface MHC class II-positive cells are less successful in preparing rat islet allografts of low immunogenicity than methods of positive cell selection. Pure islet beta-cells are immunogenic as an allograft but illicit a milder and less-acute immune attack than undissociated islet tissue. Nonendocrine and damaged islet cells are suspected of enhancing the rapidity and intensity of the cytotoxic reaction. Survival of allografted beta-cells is markedly prolonged by the presence of islet endocrine non-beta-cells within the graft. The mechanisms underlying this effect have not yet been elucidated; they may involve immune and metabolic interactions of the endocrine non-beta-cells. We conclude that purification of islet endocrine cells represents a new and powerful method for preparing insulin-producing allografts that can survive in hosts without pharmacological immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060728     DOI: 10.2337/diab.40.7.920

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Effect of donor islet mass on metabolic normalization in streptozotocin-diabetic rats.

Authors:  B Keymeulen; H Teng; M Vetri; F Gorus; P In't Veld; D G Pipeleers
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

2.  Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft.

Authors:  Bart Keymeulen; Pieter Gillard; Chantal Mathieu; Babak Movahedi; Geert Maleux; Georges Delvaux; Dirk Ysebaert; Bart Roep; Evy Vandemeulebroucke; Miriam Marichal; Peter In 't Veld; Marika Bogdani; Christel Hendrieckx; Frans Gorus; Zhidong Ling; Jon van Rood; Daniel Pipeleers
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

3.  Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats.

Authors:  Y Nie; M Nakashima; P L Brubaker; Q L Li; R Perfetti; E Jansen; Y Zambre; D Pipeleers; T C Friedman
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity.

Authors:  D Jacobs-Tulleneers-Thevissen; K Bartholomeus; K Suenens; I Vermeulen; Z Ling; K H Hellemans; P In't Veld; M Pipeleers-Marichal; D Pipeleers
Journal:  Diabetologia       Date:  2010-04-16       Impact factor: 10.122

Review 5.  Transplantation in diabetes: a cell biological problem.

Authors:  F Purrello; D Pipeleers
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

6.  Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient.

Authors:  D Jacobs-Tulleneers-Thevissen; M Chintinne; Z Ling; P Gillard; L Schoonjans; G Delvaux; B L Strand; F Gorus; B Keymeulen; D Pipeleers
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

7.  Treatment of streptozotocin induced diabetes in male rats by immunoisolated transplantation of islet cells.

Authors:  A Akbarzadeh; D Noruzian; Sh Jamshidi; A Farhangi; M R Mehrabi; B Lame Rad; M Mofidian; A Allahverdi
Journal:  Indian J Clin Biochem       Date:  2007-03

Review 8.  Concise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes.

Authors:  Daniel Pipeleers; Thomas Robert; Ines De Mesmaeker; Zhidong Ling
Journal:  Stem Cells Transl Med       Date:  2016-07-05       Impact factor: 6.940

9.  Transplantation of purified islet cells in diabetic BB rats.

Authors:  D Pipeleers; M Pipeleers-Marichal; H Markholst; A Hoorens; G Klöppel
Journal:  Diabetologia       Date:  1991-06       Impact factor: 10.122

10.  Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.

Authors:  Robert Hilbrands; Volkert A L Huurman; Pieter Gillard; Jurjen H L Velthuis; Marc De Waele; Chantal Mathieu; Leonard Kaufman; Miriam Pipeleers-Marichal; Zhidong Ling; Babak Movahedi; Daniel Jacobs-Tulleneers-Thevissen; Diethard Monbaliu; Dirk Ysebaert; Frans K Gorus; Bart O Roep; Daniel G Pipeleers; Bart Keymeulen
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.